Triamcinolone


Thông tin thuốc gốc
Chỉ định và Liều dùng
Intra-articular
Juvenile idiopathic arthritis
Child: As triamcinolone hexacetonide: 3-12 years 0.5 mg/kg (small joints); 1 mg/kg (large joints). Hands and feet: 0.6-1 mg/kg per joint (proximal interphalangeal joint); 1-2 mg/kg per joint (metacarpophalangeal/metatarsophalangeal joints). >12-18 years 2-20 mg, adjusted according to the degree of inflammation, size of joint, and amount of articular fluid (refer to detailed product guideline). Dose may be repeated at intervals of 3-4 weeks.

Intra-articular
Bursitis, Epicondylitis, Osteoarthritis, Post-traumatic arthritis, Rheumatoid arthritis, Synovitis, Tendinitis
Adult: As triamcinolone hexacetonide: 2-20 mg, adjusted according to the degree of inflammation, size of joint, and amount of articular fluid (refer to detailed product guideline). Dose may be repeated at intervals of 3-4 weeks.
Child: 10-18 years Same as adult dose.

Periarticular
Bursitis, Epicondylitis, Synovitis, Tendinitis
Adult: As triamcinolone hexacetonide: 10-20 mg. Dosage is individualised according to the size of joint and severity of the disease.
Child: 10-18 years Same as adult dose.
Cách dùng
Should be taken with food.
Hướng dẫn pha thuốc
Susp for inj may be mixed with preservative-free lidocaine hydrochloride 1% or 2%, or other similar anaesthetics. Instructions for reconstitution may vary among countries and individual products (refer to specific product guidelines).
Tương kỵ
May cause precipitation with diluents containing parabens, phenol, or other preservatives.
Chống chỉ định
Hypersensitivity. Acute psychoses, active TB, herpes simplex keratitis, systemic mycoses, parasitosis (Strongyloides infections).
Thận trọng
Patient with cardiac insufficiency, acute CAD, hypertension, recent MI, thrombophlebitis, thromboembolism, diabetes mellitus, myasthenia gravis, Cushing’s syndrome, hypothyroidism, osteoporosis, exanthematous diseases, psychosis; gastrointestinal diseases (e.g. diverticulosis, diverticulitis, active or latent peptic ulcer, ulcerative colitis, fresh intestinal anastomoses, pyogenic infection); cataracts, glaucoma, history of ocular herpes simplex; seizure disorder, systemic sclerosis, acute glomerulonephritis, chronic nephritis, cirrhosis, infections untreatable with antibiotics, metastatic carcinoma. Not for intra-articular administration during active infection or near joints. Not for use to alleviate joint pain associated with infectious states (e.g. gonococcal or tubercular arthritis). Patient subject to stress (e.g. trauma, surgery, severe infection). Use may mask acute infection. Avoid exposure to chickenpox or measles. Avoid abrupt withdrawal. Children and elderly. Hepatic and renal impairment. Pregnancy and lactation.
Tác dụng không mong muốn
Significant: Hypercortisolism or suppression of HPA axis (prolonged use); immunosuppression (e.g. secondary infections, activation of latent infection, mask acute infections); Kaposi sarcoma (prolonged use); acute myopathy (high doses); psychiatric disturbances (e.g. insomnia, mood swings, euphoria, personality changes, severe depression, frank psychotic manifestations); exacerbation of pre-existing psychiatric conditions; septic arthritis; fluid retention, electrolyte disturbance, hypertension, myocardial rupture; hyperglycaemia; worsening of myasthenia gravis; increased IOP, open-angle glaucoma, cataracts (prolonged use); increased bone loss, osteoporotic fractures; scleroderma renal crisis; menstrual irregularities; vaginal bleeding (particularly in postmenopausal women). Rarely, anaphylactoid reactions.
Ear and labyrinth disorders: Rarely, vertigo.
General disorders and administration site conditions: Sterile abscess, post-inj erythema; pain, swelling, and necrosis at the inj site.
Skin and subcutaneous tissue disorders: Rarely, hyper- or hypo-pigmentation.
Vascular disorders: Rarely, thromboembolism.
Potentially Fatal: Strongyloides hyperinfection and dissemination; serious anaphylactoid reactions.
IM/Intra-articular/Intrabursal/Intradermal/Intralesional/Intrasynovial/Parenteral/SC/Topical: C; Intravitreal: D
Chỉ số theo dõi
Monitor weight, blood pressure, blood glucose, electrolytes, IOP, BMD; growth and development in children, HPA axis suppression.
Tương tác
Increased risk of additive hypokalaemia with Amphotericin B inj and K-depleting agents. Increased risk of acute myopathy with neuromuscular blocking agents. May inhibit the effect of anticholinesterases. Additional increase of IOP with anticholinergics (e.g. atropine). May increase or diminish the therapeutic effect of oral anticoagulants. May diminish the therapeutic effect of antidiabetics (e.g. sulfonylurea derivatives) and insulin. May diminish therapeutic effect of antihypertensive agents, including diuretics. Increase in both ciclosporin and corticosteroids activity when used concomitantly. May decrease serum concentration of isoniazid. May increase the risk of digitalis toxicity. Increased clearance with hepatic enzyme inducers (e.g. barbiturates, phenytoin, carbamazepine, rifampicin, primidone, and aminoglutethimide). May decrease clearance and increase the risk of Cushing’s syndrome and adrenal suppression with CYP3A4 inhibitors (e.g. ritonavir) including cobicistat-containing products. May decrease therapeutic effect of somatropin. Increased risk and severity of gastrointestinal bleeding and ulceration associated with NSAIDs. May decrease serum salicylate levels. Increased serum levels with oestrogen (including oral contraceptives). Neurological complications and diminished antibody response with live vaccines.
Ảnh hưởng đến kết quả xét nghiệm
May attenuate skin test reactions. May cause false-negative results with nitroblue tetrazolium test for bacterial infection. May cause a positive result with anti-doping tests.
Tác dụng
Description:
Mechanism of Action: Triamcinolone is a synthetic glucocorticoid with minimal mineralocorticoid effects. It decreases inflammation by suppressing the migration of polymorphonuclear leucocytes and reverses the increased capillary permeability, inhibiting immune reactions by decreasing the activity and volume of the lymphatic system, and prevents adrenal function at high doses.
Onset: >24 hours (intra-articular).
Duration: 4-6 weeks (intra-articular).
Pharmacokinetics:
Absorption: Slowly absorbed from the inj site.
Distribution: Crosses the placenta, enters breast milk.
Excretion: Plasma half-life: Approx 2-5 hours.
Đặc tính

Chemical Structure Image
Triamcinolone

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 31307, Triamcinolone. https://pubchem.ncbi.nlm.nih.gov/compound/Triamcinolone. Accessed Nov. 22, 2023.

Bảo quản
Store between 15-30°C. Protect from light. Do not freeze.
Phân loại MIMS
Hormon steroid
Phân loại ATC
H02AB08 - triamcinolone ; Belongs to the class of glucocorticoids. Used in systemic corticosteroid preparations.
Tài liệu tham khảo
Anon. Triamcinolone (Systemic). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 09/01/2023.

Hexatrione 2% Injection, Suspension (Medexus Pharma, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 09/01/2023.

Joint Formulary Committee. Triamcinolone Hexacetonide. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 09/01/2023.

Triamcinolone Hexacetonide 20 mg/mL Suspension for Injection (Intrapharm Laboratories Ltd.). MHRA. https://products.mhra.gov.uk. Accessed 09/01/2023.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Triamcinolone từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2024 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
  • Alpha Triamcinolone
  • Dongkwang Triamcinolone
  • Fuyuan Triamcinolon
  • Sung Won Adcock Triamcinolone
  • Triamcinolone Delhi
  • Triamvirgi
  • Tricort
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in